Merck Sharp + Dohme Corp.

Jonathan T Kern

John M Sanders

John A McCauley

Thomas J Greshock

Heather E Stevenson

Andrew William Stamford

Bernard R Neustadt

Mark T Bilodeau

Michael W Miller

Jack D Scott

Xing Dai

Hong Liu

Duane E DeMong

Marc Poirier

Hemaka Anthony Rajapakse

Joel M Harris

Kallol Basu

Vanessa L Rada

Boyoung Kim

The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

Compounds inhibiting leucine-rich repeat kinase enzyme activity

Disclosed are compounds of Formula (I): and the pharmaceutically acceptable salts thereof, wherein 'A' is S&#x2014;; &#x2014;SO&#x2014;, &#x2014;SO&#x2014;, &#x2014;O&#x2014; or NR&#x2014;, wherein Rac is H, or Calkyl and Rthrough Rare defined herein. Also disclosed are pharmaceutical formulations comprising a compound of Formula I and methods of treating, managing, or ameliorating diseases amenable to treatment, management, or amelioration by inhibition of LRRK2 kinase activity, for example, Parkinson's disease. 

Leucine-rich repeat kinase enzyme activity

Growing community of inventors

Souderton, PA, United States of America

Jonathan T Kern